Related references
Note: Only part of the references are listed.BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
Evan Warner et al.
CLINICAL CANCER RESEARCH (2021)
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Gillian Vandekerkhove et al.
NATURE COMMUNICATIONS (2021)
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Elie Ritch et al.
CLINICAL CANCER RESEARCH (2020)
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Yingming Li et al.
CLINICAL CANCER RESEARCH (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Vincenza Conteduca et al.
EUROPEAN UROLOGY (2019)
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Gillian Vandekerkhove et al.
EUROPEAN UROLOGY (2019)
Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors
Parisa Mazrooei et al.
CANCER CELL (2019)
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J. Khalaf et al.
LANCET ONCOLOGY (2019)
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
Takayuki Sumiyoshi et al.
SCIENTIFIC REPORTS (2019)
ClinVar: improving access to variant interpretations and supporting evidence
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2018)
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
David Y. Takeda et al.
CELL (2018)
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
Srinivas R. Viswanathan et al.
CELL (2018)
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies et al.
NATURE REVIEWS UROLOGY (2018)
Metastatic Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (vol 174, pg 758, 2018)
David A. Quigley et al.
CELL (2018)
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
Atish D. Choudhury et al.
JCI INSIGHT (2018)
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
Bram De laere et al.
EUROPEAN UROLOGY (2017)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn et al.
CANCER CELL (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar et al.
NATURE MEDICINE (2016)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
Christine Henzler et al.
NATURE COMMUNICATIONS (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
David Lorente et al.
NATURE REVIEWS UROLOGY (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Eddy J. Chen et al.
CLINICAL CANCER RESEARCH (2015)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
SAMBLASTER: fast duplicate marking and structural variant read extraction
Gregory G. Faust et al.
BIOINFORMATICS (2014)
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
Michael D. Nyquist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
BEDTools: a flexible suite of utilities for comparing genomic features
Aaron R. Quinlan et al.
BIOINFORMATICS (2010)
Allele-specific copy number analysis of tumors
Peter Van Loo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Share Paper
